Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances


+ show speakers and program
Philip D. Greenberg, Fred Hutchinson Cancer Center Research Center, Seattle, WA

Additional speaker to be announced
Opening Reception

9:00 p.m.-10:30 p.m.



Monday, December 3
Basic Insights Into Immune Mechanisms Promoting Cancer Development and Progression
Continental Breakfast

7:00 a.m.-8:00 a.m.
Session 1: Inflammation and Cancer Initiation

8:00 a.m.-10:00 a.m.

Spontaneous and induced T cell responses to tumors
Thomas J.F. Blankenstein, Max Delbruck Center for Molecular Medicine, Berlin, Germany

T cell subsets in the tumor microenvironment
Weiping Zou, University of Michigan, Ann Arbor, MI

Paracrine regulation and intra-cellular signaling pathways
Drew M. Pardoll, Johns Hopkins University, Baltimore, MD

Short talks from proffered abstracts
Break

10:00 a.m.-10:30 a.m.
Session 2: The Tumor Microenvironment: Recent Advances

10:30 a.m.-12:30 p.m.

Reprogramming immune microenvironments in solid tumors: New approaches for improving cytotoxic therapy
Lisa M. Coussens, Oregon Health and Science University, Portland, OR

Title to be announced
Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA

Myeloid-derived suppressor cells in tumor microenvironment
Dmitry I. Gabrilovich, H. Lee Moffitt Cancer Center, Tampa, FL

Short talks from proffered abstracts
Lunch on Own / Free Time

12:30 p.m.-2:30 p.m.
Session 3: The Tumor Microenvironment: Translational Updates

2:30 p.m.-4:30 p.m.

Targeting immune escape mechanisms
Glenn Dranoff, Dana-Farber Cancer Institute, Boston, MA

Myeloid-derived suppressor cells and their role in cancer development and progression
Robert H. Vonderheide, University of Pennsylvania, Philadelphia, PA

Fatal attraction: A new story featuring the immune system and cancer
Elizabeth M. Jaffee, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD

Short talks from proffered abstracts
Poster Session A / Reception

4:30 p.m.-6:30 p.m.
Dinner on Own / Evening Off

6:30 p.m.-



Tuesday, December 4
Engineering Enhanced Immune Responses to Cancer
Continental Breakfast

7:00 a.m.-8:00 a.m.
Session 4: Checkpoint Pathways Regulating Immune Responses to Cancer

8:00 a.m.-10:00 a.m.

Translation of an OX40 agonist: Putting a foot on an immunologic gas pedal
Andrew D. Weinberg, Oregon Health & Science University, Portland, OR

Title to be announced
James P. Allison, Memorial Sloan-Kettering Cancer Center, New York, NY

Additional speaker to be announced

Short talks from proffered abstracts
Break

10:00 a.m.-10:30 a.m.
Session 5: Advances in the Development of Combinatorial Immune Based Therapies that Target Checkpoint Pathways

10:30 a.m.-12:30 p.m.

Clinical advances in therapeutic vaccines for cancer
James L. Gulley, National Cancer Institute, Bethesda, MD

Vaccines and immune modulating agents
Padmanee Sharma, University of Texas MD Anderson Cancer Center, Houston, TX

Synergistic interactions of innate and adaptive immune enhancing approaches
Charles G. Drake, Johns Hopkins University, Baltimore, MD

Short talks from proffered abstracts
Poster Session B / Lunch

12:30 p.m.-2:30 p.m.
Session 6: Innovations in Adoptive T Cell Therapy

2:30 p.m.-4:30 p.m.

CAR and TCR signaling in adoptively transferred T cells for hematologic cancers
Carl H. June, University of Pennsylvania, Philadelphia, PA

Merkel cell carcinoma therapy with viral oncoprotein-specific T cells in combination with immunostimulatory adjuvants
Paul Nghiem, University of Washington, Seattle, WA

Progress in the adoptive immunotherapy of cancer
Steven A. Rosenberg, National Cancer Institute, Bethesda, MD

Short talks from proffered abstracts
Dinner on Own / Evening Off

4:30 p.m.-



Wednesday, December 5
Immunotherapeutics: Focus on Human Studies
Continental Breakfast

7:00 a.m.-8:00 a.m.
Session 7: T Cell Precursors, Memory Subsets and Control of Adoptive Therapy

8:00 a.m.-10:00 a.m.

Functional heterogeneity in T cell memory subsets
Stanley Riddell, Fred Hutchinson Cancer Research Center, Seattle, WA

Fighting fire with fire: Eradicating cancer using stem cell-like T cells
Nicholas P. Restifo, Center for Cancer Research, National Institutes of Health, Bethesda, MD

Using viruses to enhance T cell therapy for cancer
Cliona M. Rooney, Baylor College of Medicine, Houston, TX

Title to be announced
Michael Jensen, Seattle Children's Hospital, Seattle, WA

Short talks from proffered abstracts
Break

10:00 a.m.-10:30 a.m.
Session 8: From Regulatory Pathways To Multi-Modality Immunotherapy Approaches: A Translational Paradigm

10:30 a.m.-12:30 p.m.

Innate and adaptive immune responses in premalignancy
Cornelia L. Trimble, Johns Hopkins University, Baltimore, MD

Endothelial mechanisms of T cell homing regulation in tumors
George Coukos, University of Pennsylvania, Philadelphia, PA

Combining checkpoint antibodies with in situ vaccination and with anti-tumor antibodies in the clinic
Ronald Levy, Stanford University, Stanford, CA

2 Dec - 5 Dec 2012

Miami
United States of America
meeting website